BioTrinity 2019
30 April 2019 - 01 May 2019
BioTrinity 2019 is taking place from the 30th April – 1st May at etc.venues 155 Bishopsgate in London. Now in its 13th year, BioTrinity remains the leading Life Sciences Biopartnering and Investment conference in Europe, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations.
BioTrinity 2019 incorporates significant improvements including a move to etc.venues 155 Bishopsgate, a central London location. This new venue allows us to keep all activity on one floor which will focus the energy and facilitate interaction, thereby maximising visibility for our sponsors, exhibitors, BioLaunchPad® presenters and creating even more opportunities for networking and informal meetings.
The focus of the 2019 conference is to look at 'What’s new' in the industry, and we’ll be providing updates and insight on both technical and financial developments across a wide range of key therapeutics areas – have a look at the Draft Programme.
BioTrinity is developed and organised by OBN, the not-for-profit Membership organisation supporting and bringing together the life sciences industry, their corporate partners and investors.
etc.venues 155 Bishopsgate, London EC2M 3YD
https://www.biotrinity.com/schedule-2019
19th Annual Pain Therapeutics Conference
13 May 2019 - 14 May 2019
Proudly sponsored by: CHDR, Lotus Clinical Research and MD Biosciences
The global opioids market size was valued at $22.96bn USD in 2016 and is projected to expand at a CAGR of 4.8% between 2018 and 2025. Rising prevalence of diseases that cause chronic pain, such as cancer, lower back pain, postsurgical pain, arthritis, and fibromyalgia, is driving growth.
Join Europe's leading Pain Therapeutics Conference, to explore the cutting-edge research of novel therapeutic targets in the pipeline of leading pharmaceutical companies and to discuss solutions for the challenges of clinical trial design and conduct.
The 19th annual conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, atypical opioids, migraine treatments, such as Lasmiditan and Aimovig, novel discoveries in opioid-free analgesia and the future forecast for pain therapeutics – industry leaders will uncover the latest advancements in the field. Furthermore, policy experts will provide an essential regulatory perspective for this year’s agenda, providing an exciting and comprehensive insight into the pain therapeutics market.
New case studies and regulatory perspectives will bring together the challenges and successes of both pre-clinical and clinical development to equip you with the necessary knowledge to advance the pain therapeutic industry.
#SMiPainTherapeutics
Copthorne Tara Hotel, London, UK
http://www.pain-therapeutics.co.uk/dtr
Injectable Drug Delivery 2019
15 May 2019 - 16 May 2019
The SMi Group is pleased to announce the second annual Injectable Drug Delivery conference which will be held in London on the 15th and 16th May 2019.
The global injectable drug delivery market is expected to grow from $400 billion to $1200 billion by 2046 with a CAGR of 12.8%.
Developing on last year’s success, this event assembles an international audience to include regulatory, device design, packaging and formulation professionals. The devices need to be designed for the new generation of drugs and they need to provide safety with a strong patient focus. This event is will help inspire you to help drive this industry forward and learn about the predicted market trends, critical digital and chemical developments and the push for patient compliance in a changing regulatory landscape.
This conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following:
- Life cycle management for developing devices that are both user friendly and revenue effective
- Device design considerations
- Long acting injectables and bringing these therapeutics to market with case studies
- Connected devices, GDPR and cyber security programs
- Developments in primary packaging
- Growth in transdermal delivery and subcutaneous infusion devices
- Digital health partnerships
- Large volume patch pump innovation examples
Copthorne Tara Hotel, London, UK
http://www.injectable-drug-delivery.com/areviewwl
Advances in Cell-Based Screening 2019
22 May 2019 - 24 May 2019
The third ELRIG meeting on Advances in Cell Based Profiling in Drug Discovery will be held on the 22nd and 23rd of May 2019 at the AstraZeneca R&D premises in Gothenburg. This interactive 2-day event will host leading scientists from academia and industry to discuss current and future formats for cell based assays. This time the bi-annual meeting will be accompanied by a satellite meeting on Chemical Biology on May 24th, organized by key academic infrastructures in the Nordic countries. Our aim is to create an open and inspiring environment for networking between biologists and chemists, working towards a common view on expectations from our cell assays and their use for target identification, target validation and compound profiling purposes.
Cell based assays are utilized at all stages of drug discovery to explore disease mechanisms and to identify novel molecular therapeutics. Significant advancements are being made towards cell reagents and formats that provide a more accurate biological context, aiming at improving translation to human physiology/pathophysiology. Their implementation is much needed for improving success rates in drug discovery, but there are significant challenges associated with reliable and affordable reagent supply and validation of improved translational power to justify costs. This meeting serves to explore recent advancements and to discuss their practical implementation in drug and chemical probe discovery and validation.
AstraZeneca, Gothenburg, Sweden
https://elrig.org/portfolio/2019-advances-cell-based-screening/